Next, we assessed the effect of first-line therapies on both groups: platinum doublet chemotherapy (PT), the backbone treatment for most patients with metastatic non-small cell lung cancer, and immune checkpoint blockade (ICB) given to Stage IV patients with high PD-L1 expressing tumors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.